|
|
Blood, Vol. 105, Issue 4, 1546-1548, February 15, 2005
Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg
Blood Song et al.
105: 1546
Supplemental materials for: Song et al, Vol 105, Issue 4, 1546-1548
Files in this Data Supplement:
- Figure S1. The effect of anti-erythrocyte antibody on the reversal of thrombocytopenia correlates with erythrocyte destruction in the same animals (PDF, 55 KB) -
C57BL/6 mice were injected with 2 µg anti-platelet antibody on days 0 to 3 (up arrow). All mice received an injection of 2g/kg of IVIg (open box), 50 µg TER119 (open triangle), or 200µL PBS (closed triangle) on day 2 (down arrow). Blood samples were taken daily, the platelet count (A) and erythrocyte count (B) were assessed. The x-axis denotes the days; the y-axis denotes the platelet count (A) or the fold change of erythrocytes over PBS-treated group (B); n=7 for each group. Data are expressed as mean ± SEM.
- Figure S2. In vitro binding of IVIg, anti-D, and monoclonal antibodies to erythrocytes. (JPEG, 37 KB)
-
Washed murine (A) or human (B) erythrocytes (50 µL) from an RhD+ donor were incubated with IVIg (25mg/mL of Gamimune, 10%, Lot 26N1LL1; Bayer, Elkhart, IN), anti-D (1.25 µg/mL of WinRh0; Cangene, Winnipeg, MB, Canada) or the indicated monoclonal antibodies (25 µg/mL), TER-119, M1/69 or 30-F1 at 37°C for 30 minutes. The cells were then washed twice with PBS followed by incubation with 10 µg/mL FITC-labeled anti–rat IgG (TER-119, M1/69 and 30-F1) or FITC-labeled anti–human IgG (IVIg and anti-D) for 30 minutes at 22°C. The cells were washed 3 additional times, and acquired for fluorescence on a FACScan flow cytometer. Nil indicates secondary antibody alone.
| |
